Gene therapy firm Avexis has unveiled plans to invest $60 million to expand is manufacturing center in Durham, NC. The new center was first announced in May of last year and once complete will create 200 jobs.   A Novartis company headquartered in Bannockburn, IL, AveXis’ initial product candidate, AVXS-101, now known as Zolgensma (onasemnogene abeparvovec-xioi), is an investigational gene replacement therapy for the treatment of spinal muscular atrophy (SMA) Type 1. Zolgensma is designed to add...